Comorbidity burden and outcomes of endoscopic ultrasound‐guided treatment of pancreatic fluid collections: Multicenter study with nationwide data‐based validation
Digestive Endoscopy · 2025
DOI: 10.1111/den.14924 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Digestive Endoscopy, 2025. Verfasst von Tsuyoshi Hamada und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Endosonography, Ultrasonography, Interventional, Drainage, Pancreatic Diseases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Science Foundation, the Ministry of Health, Labour, and Welfare, Japan, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Objectives
The appropriate holistic management is mandatory for successful endoscopic ultrasound (EUS)‐guided treatment of pancreatic fluid collections (PFCs). However, comorbidity status has not been fully examined in relation to clinical outcomes of this treatment.
Methods
Using a multi‐institutional cohort of 406 patients receiving EUS‐guided treatment of PFCs in 2010–2020, we examined the associations of Charlson Comorbidity Index (CCI) with in‐hospital mortality and other clinical outcomes. Multivariable logistic regression analysis was conducted with adjustment for potential confounders. The findings were validated using a Japanese nationwide inpatient database including 4053 patients treated at 486 hospitals in 2010–2020.
Results
In the clinical multi‐institutional cohort, CCI was positively associated with the risk of in‐hospital mortality ( P trend < 0.001). Compared to patients with CCI = 0, patients with CCI of 1–2, 3–5, and ≥6 had adjusted odds ratios (95% confidence intervals) of 0.76 (0.22–2.54), 5.39 (1.74–16.7), and 8.77 (2.36–32.6), respectively. In the nationwide validation cohort, a similar positive association was observed; the corresponding odds ratios (95% confidence interval) were 1.21 (0.90–1.64), 1.52 (0.92–2.49), and 4.84 (2.63–8.88), respectively ( P trend < 0.001). The association of higher CCI with longer length of stay was observed in the nationwide cohort ( P trend < 0.001), but not in the clinical cohort ( P trend = 0.18). CCI was not associated with the risk of procedure‐related adverse events.
Conclusions
Higher levels of CCI were associated with a higher risk of in‐hospital mortality among patients receiving EUS‐guided treatment of PFCs, suggesting the potential of CCI in stratifying the periprocedural mortality risk.
Trial registration
The research based on the clinical data from the WONDERFUL cohort was registered with UMIN‐CTR (registration number UMIN000044130).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
- Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
- Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Hyogo, Japan.
- Department of Health Services Research, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
- Department of Gastroenterology and Hepatology, Faculty of Medicine, Kindai University, Osaka, Japan.
- First Department of Internal Medicine, Gifu University Hospital, Gifu, Japan.
ORCID-Profile: Tsuyoshi Hamada, Mamoru Takenaka, Takuji Iwashita, Hideyuki Shiomi, Toshio Fujisawa, Ichiro Yasuda, Hiroyuki Isayama, Yousuke Nakai
Förderung
- Takeda Science Foundation
- the Ministry of Health, Labour, and Welfare, Japan
- Japan Society for the Promotion of Science
- Daiichi Sankyo Company
Zitieren
APA
Hamada, T., Masuda, A., Michihata, N., Saito, T., Tsujimae, M., Takenaka, M., Omoto, S., Iwashita, T., Uemura, S., Ota, S., Shiomi, H., Fujisawa, T., Takahashi, S., Matsubara, S., Suda, K., Matsui, H., Maruta, A., Yoshida, K., Iwata, K., …, & WONDERFUL study group in Japan and collaborators (2025). Comorbidity burden and outcomes of endoscopic ultrasound‐guided treatment of pancreatic fluid collections: Multicenter study with nationwide data‐based validation. Digestive Endoscopy. https://doi.org/10.1111/den.14924
Vancouver
Hamada T, Masuda A, Michihata N, Saito T, Tsujimae M, Takenaka M, et al. Comorbidity burden and outcomes of endoscopic ultrasound‐guided treatment of pancreatic fluid collections: Multicenter study with nationwide data‐based validation. Digestive Endoscopy. 2025. doi:10.1111/den.14924
BibTeX
@article{Hamada2025,
author = {Hamada, Tsuyoshi and Masuda, Atsuhiro and Michihata, Nobuaki and Saito, Tomotaka and Tsujimae, Masahiro and Takenaka, Mamoru and Omoto, Shunsuke and Iwashita, Takuji and Uemura, Shinya and Ota, Shogo and Shiomi, Hideyuki and Fujisawa, Toshio and Takahashi, Sho and Matsubara, Saburo and Suda, Kentaro and Matsui, Hiroki and Maruta, Akinori and Yoshida, Kensaku and Iwata, Keisuke and Okuno, Mitsuru and Hayashi, Nobuhiko and Mukai, Tsuyoshi and Fushimi, Kiyohide and Yasuda, Ichiro and Isayama, Hiroyuki and Yasunaga, Hideo and Nakai, Yousuke and WONDERFUL study group in Japan and collaborators, WONDERFUL study group in Japan and collaborators},
title = {Comorbidity burden and outcomes of endoscopic ultrasound‐guided treatment of pancreatic fluid collections: Multicenter study with nationwide data‐based validation},
journal = {Digestive Endoscopy},
year = {2025},
doi = {10.1111/den.14924}
}
EUVIMED